Sign In
Buy NMRA
$1.61
+0.0100 (+0.625%)
At Close: Aug 05, 2026
Neumora's depression drug fails trial, sinking shares
03:15pm, Thursday, 02'nd Jan 2025
CNBC's Angelica Peebles joins 'Power Lunch' to discuss Neumora's depression drug failing its trial results.
Neumora Therapeutics shares plummet as Phase 3 depression drug trial disappoints
11:19am, Thursday, 02'nd Jan 2025
Neumora Therapeutics shares tumbled over 83% on Thursday after its experimental drug for major depressive disorder (MDD), navacaprant, failed to demonstrate significant benefits in the pivotal Phase 3
Neumora Therapeutics Stock Tanks as Its Depression Drug Misses Goals
10:55am, Thursday, 02'nd Jan 2025
Neumora Therapeutics (NMRA) shares crashed 80% to an all-time low Thursday when the biopharmaceutical firm announced that a late-stage study of its experimental treatment for depression did not meet i
Neumora Therapeutics' stock craters after trial of major depressive disorder fails to meet main goals
10:27am, Thursday, 02'nd Jan 2025
News is a setback for the clinical-stage biotech and a drug that proved successful in earlier trials
Neumora Therapeutics Stock Crashes 83% After Depression Drug Flops
09:00am, Thursday, 02'nd Jan 2025
Neumora Therapeutics stock collapsed Thursday after its experimental depression treatment failed in the first of three studies. The post Neumora Therapeutics Stock Crashes 83% After Depression Drug Fl
Neumora Therapeutics' depression drug fails to meet main goal of late-stage study
07:18am, Thursday, 02'nd Jan 2025
Neumora Therapeutics said on Thursday its experimental drug to treat depression failed to meet the main goal of a late-stage study.
Neumora Therapeutics Reports Data from KOASTAL-1 Study of Navacaprant in Major Depressive Disorder
07:00am, Thursday, 02'nd Jan 2025
Study did not demonstrate statistically significant improvement on primary endpoint of reduction in depressive symptoms as measured by MADRS total score compared to placebo
Neumora: Koastal-1 Readout For MDD Treatment Is First Study On Deck
01:11pm, Tuesday, 24'th Dec 2024
Neumora Therapeutics is set to release data from the phase 3 KOASTAL-1 study using Navacaprant for the treatment of patients with MDD by the end of 2024; other data in 2025. Navacaprant showed signifi
This biotech's stock could double if its treatment for major depressive disorder succeeds, says Mizuho
11:03am, Wednesday, 13'th Nov 2024
Mizuho reiterated its bullish stance on biotech Neumora Therapeutics Inc. on Wednesday, and predicted a positive outcome when the company reports data from a late-stage trial of its treatment for majo
Neumora Therapeutics, Inc. (NMRA) Q3 2024 Earnings Call Transcript
11:50am, Tuesday, 12'th Nov 2024
Neumora Therapeutics, Inc. (NASDAQ:NMRA ) Q3 2024 Earnings Conference Call November 12, 2024 8:00 AM ET Company Participants Helen Rubinstein – Vice President of Investor Relations Henry Gosebruch �
Neumora Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
07:00am, Tuesday, 12'th Nov 2024
Phase 3 data from KOASTAL-1 study of navacaprant in MDD expected around the end of 2024; KOASTAL-2 and KOASTAL-3 topline data expected in the first half of 2025
Neumora Therapeutics to Participate in Upcoming Conferences in November
07:00am, Wednesday, 06'th Nov 2024
WATERTOWN, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven clinical and
Neumora Therapeutics to Host Key Opinion Leader Roundtable to Discuss the Potential of Navacaprant in Neuropsychiatric Disorders
07:00am, Wednesday, 14'th Aug 2024
Roundtable discussion to take place on Thursday, September 12 at 8:00 a.m. ET Roundtable discussion to take place on Thursday, September 12 at 8:00 a.m. ET
Neumora Therapeutics Announces Initiation of Phase 1b Study of NMRA-511 for Treatment of Alzheimer's Disease Agitation
07:00am, Thursday, 20'th Jun 2024
NMRA-511 is a highly potent and selective, best-in-class, antagonist of the vasopressin 1a receptor, which is known to play a role in regulation of aggression, stress and anxiety response
Neumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression
07:00am, Tuesday, 14'th May 2024
Potential to alleviate unmet need associated with depressed mood and anhedonia in bipolar depression; navacaprant has demonstrated the ability to improve these symptoms in MDD in a Phase 2 study
